Hospital
Beaufort County Memorial Hospital
Beaufort County Memorial Hospital was paid $35.85M by Medicaid between Jan 2018 and Dec 2024, across 305 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 13% of everything it billed.
33Billing provider infoBEAUFORT COUNTY MEMORIAL HOSPITAL
BEAUFORT, SC 29902
BEAUFORT, SC 29902
33aNPI1366436073assigned 09/08/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.85M
24GClaims944,355
24DCodes billed305
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#8 of 115
Median peer was paid$2.47M
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 159,168 | $4.88M | |
| 2019 | 167,808 | $5.56M | |
| 2020 | 138,840 | $5.68M | |
| 2021 | 139,821 | $5.82M | |
| 2022 | 132,238 | $5.78M | |
| 2023 | 113,038 | $4.87M | |
| 2024incomplete | 93,442 | $3.27M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 13% | 28,046 | 24,320 | $4.63M |
| 80053 | Comprehensive metabolic panel | 12% | 46,218 | 36,382 | $4.28M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.9% | 27,730 | 8,489 | $2.11M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 5.5% | 30,959 | 9,425 | $1.96M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 5.0% | 2,661 | 1,136 | $1.78M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 4.7% | 13,273 | 8,272 | $1.70M |
| 96367 | 4.7% | 3,100 | 1,454 | $1.69M | |
| 96361 | Intravenous infusion, hydration; each additional hour | 4.5% | 13,709 | 10,016 | $1.60M |
| J7050 | Infusion, normal saline solution, 250 cc | 4.0% | 5,722 | 1,734 | $1.43M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.7% | 34,725 | 10,288 | $1.34M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.0% | 9,430 | 5,877 | $1.06M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.0% | 7,804 | 7,353 | $707K |
293 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.9% | 12,283 | $688K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 15,277 | $603K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.5% | 3,349 | $526K |
| 99283 | Emergency room visit (moderate) | 1.4% | 25,259 | $504K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.3% | 2,691 | $481K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.2% | 1,614 | $423K |
| 81025 | 1.2% | 12,789 | $415K | |
| 87070 | 1.1% | 1,821 | $389K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 1.1% | 2,886 | $380K |
| 87081 | <1% | 7,670 | $327K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 2,527 | $320K |
| J3490 | Unclassified drugs | <1% | 13,143 | $282K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,534 | $254K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,184 | $250K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 15,480 | $247K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,385 | $227K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 488 | $201K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 4,613 | $169K |
| 99284 | Emergency room visit (serious) | <1% | 21,370 | $164K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 373 | $162K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,699 | $158K |
| 81001 | <1% | 29,463 | $143K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 74 | $138K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 942 | $133K |
| 93971 | <1% | 1,110 | $132K | |
| 87486 | <1% | 1,923 | $131K | |
| J1815 | Injection, insulin, per 5 units | <1% | 261 | $128K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,912 | $112K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 4,380 | $108K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,710 | $105K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,165 | $98K |
| 73630 | <1% | 2,050 | $94K | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,317 | $90K |
| 97162 | <1% | 2,323 | $89K | |
| 73610 | <1% | 1,721 | $86K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 134 | $83K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,728 | $82K |
| 76377 | <1% | 2,422 | $81K | |
| 74018 | <1% | 2,142 | $79K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 882 | $77K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 15,933 | $76K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,960 | $75K |
| 92523 | <1% | 1,038 | $73K | |
| 84702 | <1% | 4,950 | $67K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 55,237 | $65K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,079 | $65K |
| 73562 | <1% | 1,828 | $64K | |
| 87400 | <1% | 4,281 | $64K | |
| 73030 | <1% | 1,827 | $61K | |
| 71045 | Radiologic examination, chest; single view | <1% | 12,170 | $60K |
| 72100 | <1% | 1,997 | $58K | |
| 73130 | <1% | 937 | $55K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 231 | $55K |
| 99285 | Emergency room visit (most serious) | <1% | 13,304 | $53K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,905 | $52K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,427 | $52K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 416 | $48K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,287 | $46K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 6,276 | $45K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,946 | $44K |
| 73560 | <1% | 1,044 | $41K | |
| G0378 | Hospital observation service, per hour | <1% | 8,072 | $41K |
| 83735 | <1% | 11,315 | $40K | |
| 73502 | <1% | 1,111 | $38K | |
| 86592 | <1% | 3,597 | $37K | |
| 87210 | <1% | 1,729 | $35K | |
| 73110 | <1% | 655 | $32K | |
| 93922 | <1% | 167 | $31K | |
| 88304 | <1% | 66 | $31K | |
| V2632 | Posterior chamber intraocular lens | <1% | 18 | $29K |
| 72040 | <1% | 705 | $29K | |
| 86885 | <1% | 3,282 | $28K | |
| 84484 | <1% | 13,043 | $28K | |
| 97166 | <1% | 379 | $26K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,420 | $26K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 12 | $23K |
| 76830 | Ultrasound, transvaginal | <1% | 539 | $23K |
| 76642 | <1% | 414 | $22K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,304 | $21K |
| 87150 | <1% | 1,387 | $21K | |
| 85730 | <1% | 5,885 | $18K | |
| 86140 | <1% | 17,509 | $18K | |
| 77066 | Tomosynthesis, mammo | <1% | 195 | $16K |
| 0002A | <1% | 450 | $16K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,856 | $15K |
| 97116 | <1% | 792 | $14K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,858 | $14K |
| 72141 | <1% | 34 | $13K | |
| 87077 | <1% | 1,610 | $13K | |
| 96376 | <1% | 5,228 | $12K | |
| 82553 | <1% | 8,166 | $12K | |
| 0001A | <1% | 323 | $11K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 379 | $11K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 545 | $11K |
| 42830 | <1% | 25 | $11K | |
| 87040 | <1% | 3,994 | $11K | |
| 94760 | <1% | 2,982 | $10K | |
| 73140 | <1% | 104 | $10K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,294 | $10K |
| 72170 | <1% | 498 | $10K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 121 | $9K |
| 74022 | <1% | 601 | $9K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,426 | $9K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,123 | $9K |
| 84145 | <1% | 2,507 | $9K | |
| 82728 | <1% | 2,757 | $8K | |
| 80061 | Lipid panel | <1% | 6,723 | $8K |
| 76770 | <1% | 130 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,708 | $8K |
| 87420 | <1% | 107 | $7K | |
| 85018 | <1% | 2,154 | $7K | |
| 97164 | <1% | 275 | $7K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,641 | $7K |
| 85610 | <1% | 6,528 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $6K |
| 76801 | <1% | 1,021 | $6K | |
| 86900 | <1% | 2,640 | $6K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 215 | $6K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 70 | $6K |
| 92526 | <1% | 489 | $6K | |
| 83690 | <1% | 8,425 | $6K | |
| 12001 | <1% | 25 | $6K | |
| 83615 | <1% | 3,230 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,677 | $6K |
| 83021 | <1% | 1,851 | $6K | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,508 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,316 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 32 | $5K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 62 | $5K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,353 | $4K |
| 71250 | <1% | 58 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,201 | $4K |
| 82607 | <1% | 2,007 | $4K | |
| 80069 | <1% | 473 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,133 | $4K |
| 82330 | <1% | 351 | $4K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 442 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,351 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,157 | $3K |
| 85378 | <1% | 2,307 | $3K | |
| 93880 | <1% | 13 | $3K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 980 | $3K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,054 | $3K |
| 93970 | <1% | 33 | $3K | |
| 93017 | <1% | 385 | $3K | |
| 73590 | <1% | 131 | $3K | |
| 84439 | <1% | 4,255 | $3K | |
| 0071A | <1% | 72 | $3K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 356 | $2K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 605 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 79 | $2K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,438 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,250 | $2K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 890 | $2K |
| 82043 | <1% | 1,672 | $2K | |
| 85044 | <1% | 3,416 | $2K | |
| 87075 | <1% | 597 | $2K | |
| 86901 | <1% | 2,637 | $2K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 763 | $2K |
| 97165 | <1% | 27 | $2K | |
| 83540 | <1% | 2,604 | $2K | |
| 0072A | <1% | 44 | $2K | |
| 83880 | <1% | 3,146 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,896 | $2K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,901 | $2K |
| 76536 | <1% | 26 | $2K | |
| 82550 | <1% | 2,789 | $1K | |
| 82950 | <1% | 1,523 | $1K | |
| 82570 | <1% | 927 | $1K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,208 | $1K |
| 84156 | <1% | 1,179 | $1K | |
| 83605 | <1% | 3,522 | $1K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 51 | $1K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,190 | $1K |
| 84100 | <1% | 739 | $1K | |
| 0003A | <1% | 41 | $1K | |
| 93976 | <1% | 550 | $1K | |
| 43235 | <1% | 14 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,236 | $1K |
| 70486 | <1% | 29 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,238 | $1K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,554 | $1K |
| 85014 | <1% | 2,216 | $1K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 30 | $1K |
| 97168 | <1% | 12 | $1K | |
| 86803 | <1% | 1,529 | $1K | |
| 87581 | <1% | 1,917 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 57 | $1K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,940 | $1K |
| 73080 | <1% | 14 | $907.76 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,619 | $849.14 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 66 | $787.50 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,069 | $784.10 |
| 59025 | Fetal non-stress test | <1% | 41 | $677.60 |
| 86336 | <1% | 233 | $649.54 | |
| 77336 | <1% | 36 | $569.95 | |
| 82105 | <1% | 809 | $568.92 | |
| 73090 | <1% | 13 | $560.70 | |
| 84466 | <1% | 1,668 | $555.99 | |
| 97161 | <1% | 65 | $537.35 | |
| 84550 | <1% | 1,237 | $515.20 | |
| 87340 | <1% | 2,172 | $489.64 | |
| 87493 | <1% | 547 | $480.16 | |
| 72081 | <1% | 12 | $444.60 | |
| 76857 | <1% | 278 | $348.14 | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 203 | $347.83 |
| 84703 | <1% | 210 | $339.92 | |
| 84146 | <1% | 27 | $322.76 | |
| 82272 | <1% | 12 | $300.97 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 79 | $296.71 |
| 73564 | <1% | 16 | $292.02 | |
| 85027 | <1% | 1,723 | $245.61 | |
| 97163 | <1% | 12 | $235.47 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,876 | $227.31 |
| 87186 | <1% | 3,275 | $224.48 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 16 | $220.52 |
| 82746 | <1% | 479 | $193.92 | |
| 84163 | <1% | 100 | $173.85 | |
| 83874 | <1% | 6,771 | $166.03 | |
| 97167 | <1% | 18 | $153.32 | |
| 87045 | <1% | 18 | $145.14 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 14 | $120.01 |
| 80076 | <1% | 74 | $107.93 | |
| 86038 | <1% | 135 | $95.15 | |
| 86762 | <1% | 462 | $52.81 | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 16 | $34.50 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 721 | $33.69 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 350 | $21.89 |
| 82150 | <1% | 1,160 | $15.21 | |
| 87088 | <1% | 2,157 | $10.65 | |
| 85652 | <1% | 2,639 | $10.08 | |
| 82247 | <1% | 45 | $8.68 | |
| 82009 | <1% | 26 | $8.46 | |
| 86308 | <1% | 30 | $6.80 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 477 | $1.96 |
| 00731 | 0% | 58 | $0.00 | |
| 87806 | 0% | 2,213 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 215 | $0.00 |
| 82805 | 0% | 296 | $0.00 | |
| 86696 | 0% | 30 | $0.00 | |
| 83970 | 0% | 152 | $0.00 | |
| 86708 | 0% | 15 | $0.00 | |
| 88312 | 0% | 35 | $0.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 0% | 193 | $0.00 |
| 36600 | 0% | 25 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 88 | $0.00 |
| 82947 | 0% | 53 | $0.00 | |
| 78815 | Positron emission tomography (PET) for limited area imaging | 0% | 12 | $0.00 |
| 85041 | 0% | 287 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 98 | $0.00 |
| 87641 | 0% | 15 | $0.00 | |
| 85007 | 0% | 31 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 31 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 14 | $0.00 |
| 10060 | 0% | 12 | $0.00 | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 0% | 24 | $0.00 |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 14 | $0.00 |
| P9016 | Red blood cells, leukocytes reduced, each unit | 0% | 13 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 28 | $0.00 |
| 99152 | 0% | 18 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 42 | $0.00 |
| 82565 | 0% | 47 | $0.00 | |
| 90715 | 0% | 17 | $0.00 | |
| 84295 | 0% | 38 | $0.00 | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 0% | 39 | $0.00 |
| 80055 | 0% | 15 | $0.00 | |
| 82677 | 0% | 523 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 140 | $0.00 |
| 83550 | 0% | 609 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 1,569 | $0.00 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 49 | $0.00 |
| J1097 | Phenylephrine 10.16 mg/ml and ketorolac 2.88 mg/ml ophthalmic irrigation solution, 1 ml | 0% | 18 | $0.00 |
| 82435 | 0% | 15 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 16 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 98 | $0.00 |
| 94761 | 0% | 76 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 172 | $0.00 |
| 86695 | 0% | 64 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| 86430 | 0% | 15 | $0.00 | |
| 86706 | 0% | 15 | $0.00 | |
| 96368 | 0% | 39 | $0.00 | |
| 90686 | 0% | 28 | $0.00 | |
| 84132 | 0% | 58 | $0.00 | |
| 86704 | 0% | 14 | $0.00 | |
| 89220 | 0% | 42 | $0.00 | |
| 83520 | 0% | 22 | $0.00 | |
| 74019 | 0% | 12 | $0.00 | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 0% | 16 | $0.00 |
| 36430 | 0% | 12 | $0.00 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 0% | 31 | $0.00 |
| 00813 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBAXLEY, EDMOND (CEO)
| Provider | Location | Paid |
|---|---|---|
| Beaufort County Memorial Hospital | Varnville, SC | $1.42M |
| Beaufort County Memorial Hospital | Beaufort, SC | $1.34M |
| Beaufort County Memorial Hospital | Beaufort, SC | $1.06M |
| Beaufort County Memorial Hospital | Port Royal, SC | $146K |
| Beaufort County Memorial Hospital | Beaufort, SC | $39K |
| Beaufort County Memorial Hospital | Beaufort, SC | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.